Search results for " breakthrough pain"

showing 8 items of 8 documents

Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.

2014

Abstract The aim of this randomized, crossover, comparison study was to assess the analgesic and adverse effects of 2 nasal preparations, intranasal fentanyl (INFS) and fentanyl pectin nasal spray (FPNS), for breakthrough pain, given in doses proportional to opioid basal regimen. Each patient randomly received INFS or FPNS in doses proportional to opioid dosages used for background analgesia for 2 pairs of episodes. For each episode of breakthrough pain, pain intensity and adverse effects intensity were recorded just before starting the INFS or FPNS (T0) and 5 minutes (T5), 10 minutes (T10), and 20 minutes (T20) after the administration of the nasal drugs. Sixty-nine patients were studied. …

AdultMalefentanyl pectin nasal spraymedicine.medical_treatmentAnalgesicSettore MED/42 - Igiene Generale E ApplicataFentanylrapid-onset opioidsNeoplasmsparasitic diseasesMedicineHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overDose-Response Relationship Drugbusiness.industryBreakthrough Painintranasal fentanylNasal SpraysMiddle AgedCancer pain; breakthrough pain; fentanyl pectin nasal spray; intranasal fentanyl; rapid-onset opioidsAnalgesics OpioidFentanylRegimenAnesthesiology and Pain MedicineCross-Sectional StudiesNeurologyOpioidNasal sprayAnesthesiaPectinsNasal administrationFemaleNeurology (clinical)businessCancer painmedicine.drugThe journal of pain
researchProduct

The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting.

2013

Abstract The dose of rapid onset opioids to be given for breakthrough cancer pain (BTcP) is controversial. Dose proportional to the basal opioid regimen seem to be safe and effective in hospital units. However, data in other less protected settings, like home care, are lacking. The aim of this open-label study was to assess the efficacy and safety in a group of patients with BTcP followed at home, after giving a dose of fentanyl buccal tablets (FBT) proportional to the opioid basal regimen, skipping the steps for dose titration. Consecutive patients admitted to a home care program presenting BTcP episodes and receiving stable doses of opioids for background pain were selected. Data from fou…

MalePain medicineSettore MED/41 - AnestesiologiaOpioidSettore MED/42 - Igiene Generale E ApplicataHome careFentanylDose-Response RelationshipBuccalBreakthrough-episodic painNeoplasmsmedicine80 and overHumansCancer painAdverse effectAgedPain MeasurementAged 80 and overAnalgesicsDose-Response Relationship Drugbusiness.industryBreakthrough PainAdministration BuccalBuccal administrationMiddle AgedFentanyl buccal tabletHome Care ServicesAnalgesics OpioidOpioidsFentanylRegimenTreatment OutcomeBasal (medicine)OpioidOncologyCancer pain; Breakthrough-episodic pain; Fentanyl buccal tablet; Opioids; Home careAnesthesiaAdministrationFemaleBreakthrough-episodic pain; Cancer pain; Fentanyl buccal tablet; Home care; Opioids; Administration Buccal; Aged; Aged 80 and over; Analgesics Opioid; Breakthrough Pain; Dose-Response Relationship Drug; Female; Fentanyl; Home Care Services; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Tablets; Treatment Outcome; OncologyDrugCancer painbusinessmedicine.drugTablets
researchProduct

Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

2006

Supplemental dosing of an opioid is the main treatment suggested to manage breakthrough pain in cancer patients. The intravenous route has been proven to be safe and effective, providing rapid analgesia in patients receiving oral morphine. Transdermal buprenorphine (TTS-BUP) is increasingly used in cancer pain management, but this drug has been labeled as a difficult drug to use in combination with other opioids. The aim of this open-label study was to verify the safety and effectiveness of intravenous morphine (IV-MO) for the treatment of episodic pain in cancer patients receiving TTS-BUP. A consecutive sample of 29 cancer patients, who were treated with TTS-BUP, reported an acceptable bas…

Malecancer painPalliative careExacerbationtransdermal buprenorphinePainOpioidAdministration CutaneousInjectionsNeoplasmsmedicineSecondary PreventionHumansepisodic breakthrough painDosingAdverse effectbreakthrough pain; cancer pain; Intravenous morphine; opioids; transdermal buprenorphine; Administration Cutaneous; Analgesics Opioid; Buprenorphine; Drug Combinations; Female; Humans; Injections Intravenous; Male; Middle Aged; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Secondary Prevention; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Nursing (all)2901 Nursing (miscellaneous)General NursingPain MeasurementAnalgesicsMorphinebusiness.industryPalliative CareopioidsIntravenous morphineMiddle Agedbreakthrough painBuprenorphineAnalgesics Opioidtransdermal buprenorphine.Drug CombinationsCutaneousAnesthesiology and Pain MedicineTreatment OutcomeNeurologyOpioidAnesthesiaAdministrationInjections IntravenousMorphineFemaleNeurology (clinical)IntravenousCancer painbusinesssafety and effectiveness of intravenous morphinemedicine.drugBuprenorphineJournal of pain and symptom management
researchProduct

Breakthrough pain in patients with abdominal cancer pain.

2014

Abstract OBJECTIVE: Characterization of breakthrough cancer pain (BTcP) in patients with abdominal cancer is lacking. The aim of this study was to assess the characteristics of BTcP in patients with abdominal cancer pain. PATIENTS AND METHODS: In an observational cohort study, from a consecutive sample of patients admitted to a pain relief and supportive care unit for a period of 13 months, patients with abdominal disease due to cancer, including primary cancer or metastases, were assessed for the presence of chronic abdominal pain; its mechanism, intensity of background pain, and pain flares, which were distinguishable from the baseline pain, were recorded. Patients presenting with pain fl…

Malecancer painmedicine.medical_specialtyPalliative careAnalgesicSettore MED/41 - AnestesiologiaDiseaseSettore MED/42 - Igiene Generale E ApplicataCohort StudiesNeoplasmsInternal medicinemedicineHumansPain ManagementIn patientcancer pain; breakthrough pain; abdominal pain; epidemiology; opioidsNeoplasm MetastasisAgedPain MeasurementAnalgesicsbusiness.industryPalliative Careabdominal painopioidsCancerbreakthrough painmedicine.diseaseAnesthesiology and Pain MedicineFemaleepidemiologyObservational studyNeurology (clinical)Chronic PainCancer painbusinessCohort study
researchProduct

Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiol…

2020

Abstract Abstract Background: The different operational definitions of breakthrough cancer pain (BTcP) has generated unclear epidemiological data. Methods: A consecutive sample of patients was categorized on the basis of their background pain intensity, background analgesic treatment, and the presence of BTcP. Results: A total of 265 patients were surveyed; 117 patients had background pain and 91 patients presented peaks of pain intensity distinguishable from background pain. Of 117 patients with background pain, 49 patients were re-assessed after optimization of background analgesia (T1) within a mean of 8.2 days. Pain intensity significantly decreased in comparison with values recorded at…

Malemedicine.medical_specialtyEpidemiologyBreakthrough PainAnalgesicOpioidSettore MED/42 - Igiene Generale E ApplicataCONSECUTIVE SAMPLENeoplasmsSurveys and QuestionnairesEpidemiologyMedicineHumansPain ManagementCancer painPain MeasurementAnalgesicsbackground cancer painbusiness.industryMedicine (all)General MedicineBreakthrough pain; Cancer pain; Epidemiology; Opioids; Analgesics Opioid; Breakthrough Pain; Female; Humans; Male; Neoplasms; Pain Management; Pain Measurement; Surveys and Questionnaires; Medicine (all)breakthrough painIntensity (physics)OpioidsAnalgesics OpioidAnesthesiaepidemiologic studyFemaleCancer painbusinessbackground cancer pain; breakthrough pain; epidemiologic study
researchProduct

Breakthrough pain in oncology: A longitudinal study

2010

Abstract Context Existing studies on breakthrough pain (BP) have reported different prevalence rates because of different settings, populations, and assessment methods. These studies have used cross-sectional designs, and the relationship of BP with analgesic treatment has not been evaluated. Objectives The aim of this study was to longitudinally assess BP in cancer patients admitted to oncology units. Methods A consecutive sample of patients admitted to oncology centers was selected. At admission (T0), three months after admission (T3), and six months after admission (T6), data on background pain and BP were recorded. BP was assessed in terms of its intensity, duration, number of episodes,…

Oncologybreakthrough pain; Cancer pain; epidemiology; oncology; Acute Disease; Aged; Analgesics; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasms; Pain; Severity of Illness Index; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)Malemedicine.medical_specialtyLongitudinal studyBreakthrough PainAnalgesicPrevalencePainContext (language use)Severity of Illness Indexlongitudinal study; breakthrough pain; cancer patientsInternal medicineNeoplasmsEpidemiologymedicineHumansLongitudinal StudiesStage (cooking)Cancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedAnalgesicsbusiness.industrylongitudinal studyMiddle Agedbreakthrough painTreatment OutcomeAnesthesiology and Pain MedicineoncologyAcute DiseaseepidemiologyFemaleNeurology (clinical)cancer patientsbusinessCancer pain
researchProduct

Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.

2012

Abstract OBJECTIVES: The aim of this study was to compare the efficacy and safety of doses of fentanyl buccal tablet (FBT) proportional to doses of opioids used for background analgesia versus dose titration starting with the minimal dose for the management of breakthrough cancer pain (BTcP). METHODS: A total of 82 cancer patients with BTcP who were receiving strong opioids in doses of at least 60 mg of oral morphine equivalents and having acceptable background analgesia, were selected for a multicenter unblinded study. Forty-one patients were randomized to receive FBT in doses proportional to the daily opioid doses for four consecutive episodes of BTcP (group P). Forty-one patients underwe…

OralMaleDose titrationfentanyl buccal tabletAdministration OralOpioidDosing fentanylSettore MED/42 - Igiene Generale E ApplicataDose titrationlaw.inventionDose-Response RelationshipRandomized controlled triallawNeoplasmsFentanyl Buccal TabletMedicineHumansRapid onset opioidsDrug Dosage CalculationsCancer painAgedPain MeasurementAnalgesicsDose-Response Relationship DrugBreakthrough pain; Cancer pain; Dose titration; Fentanyl buccal tablet; Rapid onset opioids; Administration Oral; Aged; Analgesics Opioid; Breakthrough Pain; Dose-Response Relationship Drug; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Tablets; Titrimetry; Drug Dosage Calculations; Medicine (all)business.industryMedicine (all)Breakthrough PainTitrimetryCancerGeneral MedicineBuccal administrationfentanyl buccal tablet; breakthrough cancer pain; randomized clinical trialMiddle Agedmedicine.diseaserandomized clinical trialAnalgesics OpioidFentanylbreakthrough cancer painOpioidAnesthesiaAdministrationFemaleDrugbusinessCancer painmedicine.drugTabletsCurrent medical research and opinion
researchProduct

Treatment strategies for cancer patients with breakthrough pain.

2009

Breakthrough pain (BTP) is a transitory flare of pain superimposed on an otherwise stable pain pattern in patients treated with opioids. It is normally severe in intensity, has a rapid onset, has a variable duration (on average 30 min) and is considered a negative prognostic factor. OBJECTIVE: To verify the data in the literature about therapy strategies for BTP in cancer patients. METHODS: To find clinical trials investigating drug therapy for BTP. CONCLUSION: The treatment of BTP in cancer patients receiving opioids is principally based on the use of opioids, preferentially with a short onset. Fentanyl delivered by recently developed systems seems to be the best option to cover the tempor…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaBreakthrough PainPainFentanylPharmacotherapyNeoplasmsInternal medicinemedicineAnimalsHumansPharmacology (medical)In patientPain MeasurementPharmacologybusiness.industryCancerGeneral Medicinemedicine.diseaseAnalgesics OpioidFentanylClinical trialTreatment OutcomeAnesthesiaTreatment strategycancer pain opiods breakthrough painbusinessCancer painmedicine.drug
researchProduct